The article discusses the psychological barriers that contribute to low rates of colorectal cancer (CRC) screening. Many Americans, over 40%, are skipping standard CRC screening due to negative emotional associations with the disease and the tests involved. Fear, embarrassment, and disgust associated with CRC and its screening tests lead to denial and defensiveness, causing individuals to put off screening and hope for the best. Although there are various screening options available, such as colonoscopy, stool-based tests, and direct visualization tests, the overall CRC screening rates remain below the target percentage. Practical challenges, like the invasiveness and time commitment of colonoscopy,…
Author: Rutali Thakur
Metoclopramide is the only FDA-approved medication for the treatment of gastroparesis; however, it comes with a black box warning. To discuss the challenges in diagnosing and treating gastroparesis, Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine, Pharmacology, and Physiology at the Mayo Clinic in Rochester, Minnesota.
Digestive Disease Week 2023 in Chicago was a key event with significant focus on the latest data on colorectal cancer, including subsequent cancer diagnoses, cell-free DNA blood test for screening, and the impact of aspirin and NSAID use. A study revealed that 16% of early-onset colorectal cancer survivors developed a second cancer, with a higher risk among men. Another study showed a cell-free DNA blood-based test having 83% sensitivity for colorectal cancer detection and 90% specificity in an average-risk population, similar to the performance of current noninvasive screening options. In addition to colorectal cancer, there was also coverage of treatment…
The article discusses Walgreens’ latest venture into the clinical trials business through a new partnership with Parexel, a contract research organization (CRO). Walgreens aims to leverage its vast network of retail locations to provide convenient access for patients participating in clinical trials. This move follows Walgreens’ previous partnership with PRA Health Sciences in the same field. The article notes that these developments reflect the growing interest among pharmacies and healthcare organizations in the clinical trials space. By incorporating clinical trials into their services, Walgreens and other organizations seek to enhance patient engagement, provide broader access to research opportunities, and contribute…
This article discusses the use of the drug “sotagliflozin” in patients with type 2 diabetes. The article reports on the results of a study that found that sotagliflozin was effective in reducing blood sugar levels and body weight in patients with type 2 diabetes who were already taking insulin. The study also found that sotagliflozin was well-tolerated by patients and did not increase the risk of hypoglycemia. The article concludes that sotagliflozin may be a useful treatment option for patients with type 2 diabetes who are already taking insulin and are struggling to control their blood sugar levels.
The article provides an update on the pipeline of new treatments for ulcerative colitis and Crohn’s disease. It discusses several new drugs that are currently in development, including oral and injectable medications. The article also outlines the potential benefits and drawbacks of these new treatments, as well as the challenges associated with developing new drugs for these conditions. It concludes by noting that while there is still much work to be done in this area, there is reason for optimism that new treatments will be developed that can help patients with ulcerative colitis and Crohn’s disease.
Having a lot of rules and regulations is the most challenging part of being a gastroenterologist, according to Medscape’s “Gastroenterologist Compensation Report 2023.” The data comes from a Medscape “Physician Compensation Report” for 2023 that surveyed 10,011 physicians across more than 29 specialties about their income, work hours, job satisfaction and more from Oct. 7 to Jan. 17. Here is how gastroenterologists responded when asked about the most challenging part of their job, according to Medscape: Having so many rules and regulations: 18 percent
Doctors once turned to part-time work mostly as a transition into retirement. Overloaded and burned out, many in their working prime are now building entire careers as temporary physicians-for-hire. Dr. Franklyn Rocha-Cabrero, a 37-year-old neurologist, went into gig work soon after completing his training, detouring from the traditional track of joining a medical practice or hospital system. He typically takes at least 10 out of every 30 days off. And he earns an hourly rate that is usually 30% to 40% more than a hospital-staff physician would, he says.
The ways in which artificial intelligence (AI) may transform the future of medicine are making headlines across the globe. But chances are, you’re already using AI in your practice every day ― you may just not realize it. And whether you recognize the presence of AI or not, the technology could be putting you in danger of a lawsuit, legal experts say. The use of AI in your daily practice can come with hidden liabilities, say legal experts, and as hospitals and medical groups deploy AI into more areas of healthcare, new liability exposures may be on the horizon.
Olympus and Odin Vision will present at HIMSS23 European Healthcare Conference & Exhibition (June 7-9) in Lisbon, Portugal TOKYO and HAMBURG, June 5, 2023 – (JCN Newswire) – Olympus, a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, announced the plan to establish a series of Digital Excellence Centers (DECs) following acquisition of London-based Odin Vision, a cloud-AI endoscopy company with a strong portfolio of commercially available computer-aided detection/diagnostic solutions and innovation pipeline of cloud-enabled applications. The acquisition has strengthened Olympus’ recently announced strategy and initiatives in digital health and brings the promise of AI-powered real-time diagnosis and minimally…